Long‐term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2‐year follow‐up of the CHRONOS‐1 study

Author:

Dreyling Martin1,Santoro Armando2,Mollica Luigina3,Leppä Sirpa4,Follows George5,Lenz Georg6,Kim Won Seog7,Nagler Arnon8,Dimou Maria9,Demeter Judit10,Özcan Muhit11,Kosinova Marina12,Bouabdallah Krimo13,Morschhauser Franck14,Stevens Don A.15,Trevarthen David16,Munoz Javier17,Rodrigues Liana18,Hiemeyer Florian19,Miriyala Ashok20,Garcia‐Vargas Jose20,Childs Barrett H.20,Zinzani Pier Luigi21ORCID

Affiliation:

1. Department of Medicine III University Hospital, LMU Munich Germany

2. Humanitas Clinical and Research Center Rozzano Italy

3. Maisonneuve‐Rosemont Hospital Research Centre Montréal Canada

4. Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki Helsinki Finland

5. Cambridge University Hospitals NHS Foundation Trust Cambridge UK

6. Translational Oncology University Hospital Münster Münster Germany

7. Samsung Medical Center Sungkyunkwan University School of Medicine Seoul South Korea

8. Chaim Sheba Medical Center Tel Aviv University, Tel HaShomer Tel Aviv‐Yafo Israel

9. School of Medicine National and Kapodistrian University of Athens Athens Greece

10. First Department of Internal Medicine, Semmelweis University Budapest Hungary

11. Department of Internal Medicine, Division of Hematology, Ankara University Ankara Turkey

12. Kemerovo Regional Clinical Hospital Kemerovo Russian Federation

13. Department of Hematology, University Hospital of Bordeaux, Hôpital Haut‐Lévêque Pessac France

14. Univ. Lille, CHU Lille, EA 7365 ‐ GRITA ‐ Groupe de Recherche sur les formes Injectables et les Technologies Associées Lille France

15. Norton Cancer Institute Louisville Kentucky

16. Comprehensive Cancer Care and Research Institute of Colorado, LLC Englewood Colorado

17. Banner MD Anderson Cancer Center Clinic Gilbert Arizona

18. Bayer SA São Paulo Brazil

19. Pharmaceutical Division Bayer AG Berlin Germany

20. Bayer HealthCare Pharmaceuticals, Inc. Whippany New Jersey

21. Institute of Hematology “Seràgnoli”, University of Bologna Bologna Italy

Funder

Bayer

Publisher

Wiley

Subject

Hematology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3